Editorials

Treating severe malaria

BMJ 2005; 330 doi: https://doi.org/10.1136/bmj.330.7487.317 (Published 10 February 2005) Cite this as: BMJ 2005;330:317
  1. Christopher J M Whitty, clinical senior lecturer (c.whitty@lshtm.ac.uk),
  2. Evelyn Ansah, district director of health services,
  3. Hugh Reyburn, senior lecturer
  1. Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London WC1B 3DP
  2. Dangme West District Health Directorate/Research Centre, PO Box 1, Dodowa, Ghana
  3. LSHTM/KCMC/CMP Joint Malaria Programme, Box 2228, Moshi, Tanzania

    Rectal artemether may be as good as intravenous quinine

    Every year over a million children die of malaria in Africa. In many settings, especially rural ones, most fatalities due to malaria occur outside hospital, although a substantial proportion of these children will have made contact with some level of healthcare in their final illness.1 Of those who arrive at hospital, many are moribund and up to half of malaria deaths in hospitals occur within 24 hours of admission.2 Buying time by being able to start effective treatment for those with severe malaria in the community therefore has the potential to save many lives. Conventional treatment for severe malaria in Africa is intravenous or intramuscular quinine. Providing parenteral treatment with quinine in the community is usually impractical and potentially hazardous. Even in hospitals, staff are often overstretched and have some difficulty managing intravenous quinine safely.

    In this issue Aceng et al report …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe